FGT — Extreme Fibroglandular Tissue
Extreme fibroglandular tissue (category D) is the highest density classification in the BI-RADS MRI lexicon for amount of fibroglandular tissue (FGT). The breast is almost entirely composed of fibroglandular tissue with minimal visible fat on T1-weighted sequences.
Definition
In BI-RADS v2025, FGT category D indicates that the breast volume is almost entirely fibroglandular with only minimal fatty tissue interspersed. This is the MRI analogue of mammographic density category D (extremely dense), though the two assessments are made independently and may not always correlate perfectly due to differences in tissue contrast between modalities.
FGT is assessed on pre-contrast T1-weighted images (non-fat-suppressed), where fat appears bright and fibroglandular tissue appears intermediate to dark. Category D shows predominantly intermediate/dark signal with very little bright fatty signal.
FGT Classification Scale
| Category | Label | Description |
|---|---|---|
| A | Almost entirely fatty | Breast is predominantly fat with minimal FGT |
| B | Scattered fibroglandular tissue | Scattered islands of FGT within fatty tissue |
| C | Heterogeneous FGT | Heterogeneous mixture; may obscure small lesions |
| D | Extreme FGT | Almost entirely fibroglandular; minimal fat |
Imaging Appearance
- T1W (pre-contrast, non-fat-suppressed): Diffusely intermediate-to-low signal throughout the breast with minimal high-signal fatty regions. This is the sequence used for FGT classification.
- T1W fat-suppressed (pre-contrast): Uniformly low-to-intermediate signal; fat suppression eliminates the small amount of visible fat.
- T2W: Fibroglandular tissue appears intermediate; scattered small T2-bright foci may represent normal cysts or fluid in ducts — do not mistake for pathology.
- Post-contrast T1W fat-suppressed: The extensive fibroglandular volume provides a large substrate for background parenchymal enhancement (BPE), which may be marked. Focal enhancing lesions can be obscured by intense diffuse BPE.
- DWI: Dense fibroglandular tissue may show mildly restricted diffusion at baseline, which can complicate interpretation. Use ADC maps cautiously and correlate with morphologic features.
Clinical Significance
- BPE impact: Extreme FGT provides the greatest volume of enhancing parenchyma. When BPE is marked, it can obscure true enhancing lesions, reducing conspicuity — though overall MRI sensitivity remains high.
- MRI sensitivity preserved: Unlike mammography, where extreme density significantly reduces cancer detection sensitivity (masking effect), MRI sensitivity is NOT impaired by extreme FGT. Contrast enhancement dynamics remain the primary detection mechanism regardless of tissue density.
- Screening implications: Women with extreme FGT on mammography are prime candidates for supplemental MRI screening, particularly when combined with elevated lifetime risk (≥20%).
- Hormonal influence: FGT category can change with hormonal status. Premenopausal women, those on hormone replacement therapy (HRT), or those taking tamoxifen may show increased FGT. Optimally, premenopausal breast MRI is performed during week 2 of the menstrual cycle (days 7–14) to minimize FGT-related BPE.
- Reporting: BI-RADS v2025 requires FGT assessment in every breast MRI report. It is a qualitative visual estimate, not a quantitative measurement.
Board Pearl
Unlike mammographic density (where extreme density reduces sensitivity from ~85% to ~50%), extreme FGT on MRI does NOT impair diagnostic accuracy. MRI sensitivity exceeds 90% regardless of FGT level because contrast enhancement — not tissue attenuation — drives lesion detection.
Board Pearl
FGT is assessed on pre-contrast T1-weighted images without fat suppression. Do not assess FGT on post-contrast or fat-suppressed sequences, as tissue contrast is altered.
Comparison with Mammographic Density
| Feature | Mammographic Density D | MRI FGT Category D |
|---|---|---|
| Assessment basis | X-ray attenuation | T1 signal intensity |
| Sensitivity impact | Significantly reduced (~50%) | NOT reduced (>90%) |
| Masking effect | Major concern | Minimal (BPE is the concern) |
| Supplemental screening value | MRI recommended | Already the supplemental tool |
| Quantification | VOLPARA, Quantra available | Qualitative visual estimate |
Pitfalls
- Confusing FGT with BPE: FGT describes the amount of tissue (assessed pre-contrast); BPE describes the degree of enhancement (assessed post-contrast). A breast can have extreme FGT with minimal BPE, or scattered FGT with marked BPE. These are independent descriptors.
- Overcalling FGT on fat-suppressed sequences: Fat suppression removes the bright fat signal, making the breast appear more uniformly dense. Always assess FGT on the non-fat-suppressed T1W sequence.
- Assuming mammographic and MRI density correlate exactly: While they generally trend together, discordance occurs. Report each independently per its own modality criteria.
- Ignoring timing effects: Premenopausal FGT fluctuates with the menstrual cycle. Scans performed in the luteal phase may overestimate FGT and BPE.
- Dismissing focal findings in a background of extreme FGT: Even when BPE is marked, suspicious morphologic features (irregular shape, spiculated margin, washout kinetics) should prompt further evaluation.
Board Pearl
FGT and BPE are independent descriptors. FGT = how much tissue (pre-contrast). BPE = how much it enhances (post-contrast). A woman with extreme FGT can have minimal BPE, and vice versa. Report both separately.
v2025 Changes
The four-tier FGT classification (A through D) is unchanged from the 5th edition. BI-RADS v2025 continues to use the same qualitative categories. The key emphasis in v2025 is:
- Reinforcement that FGT does not affect MRI diagnostic performance (unlike mammography)
- Continued recommendation to assess FGT on pre-contrast T1W non-fat-suppressed images
- FGT remains a required element of the structured MRI report
Differential Considerations
When encountering an almost entirely dense breast on MRI, consider:
| Condition | Distinguishing Feature |
|---|---|
| Normal extreme FGT | Symmetric, bilateral, follows expected parenchymal architecture |
| Diffuse diffuse NME | Enhances abnormally on post-contrast; may show suspicious kinetics |
| Inflammatory breast cancer | Skin thickening, skin enhancement, peritumoral edema, clinical signs |
| Lymphoma / diffuse infiltration | Diffuse signal abnormality, may show restricted diffusion, clinical context |
| Post-treatment changes | History of radiation or chemotherapy; skin/trabecular thickening |